secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211964
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014
--------------------------------------------------------------------------------

- Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
- Discontinued JANX008 (EGFR-TRACTr) development after Phase 1a; resources redirected.
- Initiated clinical evaluation of JANX014 (PSMA-TRACTr); JANX007 combination with darolutamide enrolling.
- BMS collaboration milestone triggered $35M payment upon development candidate nomination.
- Appointed William Go, M.D., Ph.D. as Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/0001193125-26-211964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/janx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer